17 September 2026
Latham & Watkins Advises Tyra on US$400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Advising firms
Deal team
9 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Matt Bush Lead | Latham & Watkins LLP | Partner | corporate | Not stated |
| Nadia Patiño | Latham & Watkins LLP | Associate | corporate | Not stated |
| Rachel Staub | Latham & Watkins LLP | Associate | corporate | Not stated |
| Betty Pang | Latham & Watkins LLP | Partner | healthcare regulatory | Not stated |
| Chad Jennings | Latham & Watkins LLP | Counsel | FDA regulatory | Not stated |
| Robert Yeh | Latham & Watkins LLP | Counsel | intellectual property | Not stated |
| Andrew Wang | Latham & Watkins LLP | Associate | intellectual property | Not stated |
| Eric Cho | Latham & Watkins LLP | Partner | tax | Not stated |
| Sina Setayeshpour | Latham & Watkins LLP | Associate | tax | Not stated |
6 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 400m (US$400 million)
- What the figure measures
- Issue size
- Client
- Tyra Biosciences, Inc.Issuer
- Counterparties
- Not stated